Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio, the Company now has patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health.
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2025 Diabetes Prevention Awareness Center.